September 5, 2014
The Australian National Council on Drugs has released a report titled "Medication treatment options for amphetamine-type stimulants." The report considers withdrawal medications, treatments for amphetamine dependence, treatment of co-occurring mental health problems and treatments for other amphetamine-type stimulants. The authors found that there was no evidence to support the use of benzodiazepines for the management of sleep disturbance or agitation amongst amphetamine-type stimulant users in withdrawal, despite this being frequently recommended in clinical guidelines. The authors did find some evidence (although limited) that mirtazapine, modafinil, dexamphetamine and amineptine may be effective in reducing withdrawal symptoms in some people.
Download "Medication treatment options for amphetamine-type stimulant users" (1.75MB PDF)
This initiative is funded by the Queensland Government.